Literature DB >> 31216563

(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.

Lace M Riggs1,2, Yasco Aracava3, Panos Zanos2, Jonathan Fischell4, Edson X Albuquerque3,5, Edna F R Pereira3,5, Scott M Thompson2,4, Todd D Gould6,7,8,9.   

Abstract

Preclinical studies indicate that (2R,6R)-hydroxynorketamine (HNK) retains the rapid and sustained antidepressant-like actions of ketamine, but is spared its dissociative-like properties and abuse potential. While (2R,6R)-HNK is thought to exert its antidepressant-like effects by potentiating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated synaptic transmission, it is unknown how it exerts this effect. The acute synaptic effects of (2R,6R)-HNK were examined by recording field excitatory postsynaptic potentials (fEPSPs) and miniature excitatory postsynaptic currents (mEPSCs) in rat hippocampal slices. (2R,6R)-HNK bath application caused a rapid and persistent potentiation of AMPAR-mediated Schaffer collateral (SC)-CA1 fEPSPs in slices derived from male and female rats. The (2R,6R)-HNK-induced potentiation occurred independent of N-methyl-D-aspartate receptor (NMDAR) activity, was accompanied by a concentration-dependent decrease in paired pulse ratios, and was occluded by raising glutamate release probability. In additon, in the presence of tetrodotoxin, (2R,6R)-HNK increased the frequency, but not amplitude, of mEPSC events, confirming a presynaptic site of action that is independent of glutamatergic network disinhibition. A dual extracellular recording configuration revealed that the presynaptic effects of (2R,6R)-HNK were synapse-selective, occurring in CA1-projecting SC terminals, but not in CA1-projecting temporoammonic terminals. Overall, we found that (2R,6R)-HNK enhances excitatory synaptic transmission in the hippocampus through a concentration-dependent, NMDAR-independent, and synapse-selective increase in glutamate release probability with no direct actions on AMPAR function. These findings provide novel insight regarding (2R,6R)-HNK's acute mechanism of action, and may inform novel antidepressant drug mechanisms that could yield superior efficacy, safety, and tolerability.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31216563      PMCID: PMC6901515          DOI: 10.1038/s41386-019-0443-3

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

Review 1.  Functionally heterogeneous synaptic vesicle pools support diverse synaptic signalling.

Authors:  Simon Chamberland; Katalin Tóth
Journal:  J Physiol       Date:  2015-12-28       Impact factor: 5.182

2.  Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.

Authors:  Thu Ha Pham; Céline Defaix; Xiaoming Xu; Shi-Xian Deng; Nicolas Fabresse; Jean-Claude Alvarez; Donald W Landry; Rebecca A Brachman; Christine A Denny; Alain M Gardier
Journal:  Biol Psychiatry       Date:  2017-10-26       Impact factor: 13.382

Review 3.  A REVIEW OF KETAMINE ABUSE AND DIVERSION.

Authors:  Sean Sassano-Higgins; Dave Baron; Grace Juarez; Neevon Esmaili; Mark Gold
Journal:  Depress Anxiety       Date:  2016-06-22       Impact factor: 6.505

4.  Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.

Authors:  Allie J Widman; Lori L McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

5.  Periaqueductal Gray Glutamatergic Transmission Governs Chronic Stress-Induced Depression.

Authors:  Yu-Cheng Ho; Tzer-Bin Lin; Ming-Chun Hsieh; Cheng-Yuan Lai; Dylan Chou; Yat-Pang Chau; Gin-Den Chen; Hsien-Yu Peng
Journal:  Neuropsychopharmacology       Date:  2017-08-30       Impact factor: 7.853

6.  Acute suppression of spontaneous neurotransmission drives synaptic potentiation.

Authors:  Elena Nosyreva; Kristen Szabla; Anita E Autry; Alexey G Ryazanov; Lisa M Monteggia; Ege T Kavalali
Journal:  J Neurosci       Date:  2013-04-17       Impact factor: 6.167

7.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Authors:  Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

8.  Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.

Authors:  N Yao; O Skiteva; X Zhang; P Svenningsson; K Chergui
Journal:  Mol Psychiatry       Date:  2017-11-21       Impact factor: 15.992

9.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

10.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

View more
  10 in total

Review 1.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 2.  Mechanisms of ketamine and its metabolites as antidepressants.

Authors:  Evan M Hess; Lace M Riggs; Michael Michaelides; Todd D Gould
Journal:  Biochem Pharmacol       Date:  2021-12-27       Impact factor: 5.858

3.  Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.

Authors:  Briana K Chen; Victor M Luna; Christina T LaGamma; Xiaoming Xu; Shi-Xian Deng; Raymond F Suckow; Thomas B Cooper; Abhishek Shah; Rebecca A Brachman; Indira Mendez-David; Denis J David; Alain M Gardier; Donald W Landry; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2020-05-17       Impact factor: 7.853

4.  Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.

Authors:  Cristan A Farmer; Jessica R Gilbert; Ruin Moaddel; Jomy George; Lilian Adeojo; Jacqueline Lovett; Allison C Nugent; Bashkim Kadriu; Peixiong Yuan; Todd D Gould; Lawrence T Park; Carlos A Zarate
Journal:  Neuropsychopharmacology       Date:  2020-04-06       Impact factor: 7.853

Review 5.  Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants.

Authors:  Ronald S Duman; Satoshi Deyama; Manoela Viar Fogaça
Journal:  Eur J Neurosci       Date:  2019-12-20       Impact factor: 3.386

Review 6.  Ketamine and the Future of Rapid-Acting Antidepressants.

Authors:  Lace M Riggs; Todd D Gould
Journal:  Annu Rev Clin Psychol       Date:  2021-02-09       Impact factor: 18.561

7.  A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801.

Authors:  Patrick J Morris; Richard D Burke; Alok K Sharma; Daniel C Lynch; Leslie E Lemke-Boutcher; Shiny Mathew; Ikram Elayan; Deepa B Rao; Todd D Gould; Carlos A Zarate; Panos Zanos; Ruin Moaddel; Craig J Thomas
Journal:  Neurotoxicol Teratol       Date:  2021-05-01       Impact factor: 4.071

8.  A Unique Brain Connectome Fingerprint Predates and Predicts Response to Antidepressants.

Authors:  Samaneh Nemati; Teddy J Akiki; Jeremy Roscoe; Yumeng Ju; Christopher L Averill; Samar Fouda; Arpan Dutta; Shane McKie; John H Krystal; J F William Deakin; Lynnette A Averill; Chadi G Abdallah
Journal:  iScience       Date:  2019-12-23

9.  BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.

Authors:  Lingsha Ju; Jiaojiao Yang; Tingting Zhu; Panmiao Liu; Jianjun Yang
Journal:  BMC Psychiatry       Date:  2022-03-15       Impact factor: 3.630

Review 10.  Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.

Authors:  Songbai Xu; Xiaoxiao Yao; Bingjin Li; Ranji Cui; Cuilin Zhu; Yao Wang; Wei Yang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.